New Draft National Health Fund Ordinance on Drug Program Contracts. Reactions until July 14

  • NHF headquarters has published a draft regulation on the conditions for concluding and executing contracts such as hospital treatment in the field of drug programs
  • Opinions and comments on the project can be submitted to the National Health Fund until July 14 at sekretariat.dgl@nfz.gov.pl
  • The main changes in the design relate to the names of the scope of drug programs, resulting from the entry into force on July 1 this year. a new reimbursement list

The medical faculty again at the University of Warsaw.  First, a medical faculty

A revolution in clinics.  Experts at premiere want massive changes in POZ

drug programs. Opinions and comments on the project can be submitted until July 14

– The National Health Fund Headquarters presents a draft Regulation from the Chairman of the National Health Fund amending the Regulation laying down the conditions for the conclusion and performance of contracts such as hospital treatment in the field of drug programs, with a view to obtaining an opinion from competent authorities – informs the National Health Fund on its website.

NHF headquarters is waiting for opinions and comments on the draft regulation in question until July 14, 2022, 12:00 (the date of receipt by the Fund Headquarters counts)

Opinions and comments may only be sent in electronic version (excel) to the email address: sekretariat.dgl@nfz.gov.pl in accordance with the attached table template which can be downloaded at: https://www.nfz.gov.pl/zarzadzenia-prezesa/projekty-zarzadzen/projekt-zarzadzenia-leczenie-szpitalne-programy-lekowe,6787.html

– The regulation introduces amendments to the Regulation No. 16/2022 / DGL of the Chairman of the National Health Fund of February 11, 2022 on defining the conditions for the conclusion and performance of contracts such as hospital treatment in the field of drug programs (as amended ), adapted to the announcement of the Minister of Health of 21 June 2022 on the list of reimbursed medicines, foodstuffs for special nutritional purposes and medical devices as of 1 July 2022 (Journal of Law of the Minister of Health, item 65) – informs the National health fund.

The orthopedists agreed on the salaries.  Arranging physiotherapists

There won't be a flawless system that doctors want.  The Ministry of Justice got its way

drug programs. Rename Ranges

The main changes in the project refer to range namesamong others, the following drug programs:

  • B.70. “Treatment of patients with retinal disorders” and B.71. “Treatment with interferon-free therapy in patients with chronic hepatitis C”
  • Amendment 03.0000.301.02 from “Treatment of Chronic Hepatitis B” to “Treatment of Patients with Chronic Hepatitis B”
  • Amendment 03.0000.333.02 to “Treatment of Active Rheumatoid Arthritis and Juvenile Idiopathic Arthritis” in “Treatment of Patients with Active Rheumatoid Arthritis and Juvenile Idiopathic Arthritis”
  • Amendment 03,000,335.02 from “Treatment of active psoriatic arthritis (PsA)” in “Treatment of patients with active psoriatic arthritis (PsA)”
  • Amendment 03,0000.336.02 from “Treatment of active ankylosing spondylitis (AS)” in “Treatment of patients with active ankylosing spondylitis (AS)”
  • Amendment 03,0000.339.02 from “Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients” to “Treatment of Secondary Hyperparathyroidism in Patients Undergoing Renal Replacement Dialysis”
  • Deletion of the range 03,000,369.02 “Pariacalcitol Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients”,
    Amendment 03.0000.370.02 from “Treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD)” to “Treatment of Patients with Retinal Disease”
  • Amendment 03,0000.371.02 from “Treatment of chronic hepatitis C with interferon-free therapy” to “Treatment with interferon-free therapy in patients with chronic hepatitis C”
  • Amendment 03.0000.375.02 from “Treatment of active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)” in “Treatment of patients with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)”
  • Amendment 03,0000.386.02 from “Treatment of Congenital Autoinflammatory Syndromes” in “Treatment of Patients with Congenital Autoinflammatory Syndromes”
  • Deletion from scope 03.0000.420.02 “Treatment of Diabetic Macular Edema (DME)”.

Details of all planned changes to the draft regulation can be downloaded from the website: www.nfz.gov.pl

Diagnostics fight for power.  In the background the Law on Laboratory Medicine.  Alina Niewiadomska refers to the allegations

New NFZ report.  The fund publishes expenses for the treatment of Poland in 2021. The data is surprising

Read more about:

Leave a Comment